HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer PurposeThe HER2CLIMB-05 study (ClinicalTrials.gov identifier: NCT05132582) is investigating the efficacy and safety of adding tucatinib to trastuzumab and pertuzumab as first-line (1L) maintenance the...

We’re proud to share Dr. Erika Hamilton's latest publication in Journal of Clinical Oncology: #HER2CLIMB05, a Phase 3 study evaluating tucatinib in combo w/trastuzumab + pertuzumab as first-line maintenance therapy for HER2+ #metastaticbreastcancer.
ascopubs.org/doi/10.1200/...

Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer | CancerNetwork The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.

New data from HER2CLIMB-05: Tucatinib added to first-line maintenance therapy improves PFS in HER2+ metastatic breast cancer.
Dr. Erika Hamilton of SCRI shares insights on this promising approach.
Full Cancer Network story:
www.cancernetwork.com/view/tucatin...
#Oncology #BreastCancer #HER2CLIMB05